Objective To explore the efficacy and safety of different doses of rosuvastatin calcium in treating elderly coronary heart disease patients with hyperlipidemia .Methods Ninety elder coronary heart disease patients with hyperlipidemia were randomly divided into groups A ,B and C according to the random number table ,with 30 cases in each group .The patients in three groups were all given conventional treatment for coronary heart disease .In addition ,the patients in group A were given rosuvastatin calcium 5 mg orally,the patients in group B were given rosuvastatin calcium 10 mg orally,and the patients in group C were given rosuvastatin calcium 20 mg orally.All the patients were taken the medicine once a day after dinner .After 4 months of treatment ,the blood lipid levels ,cholesterol compliance rates and adverse events of three groups were compared.Results The levels of total cholesterol,triglycerides,low-density lipoprotein cholesterol of three groups decreased significantly in contrast with those of pre -treatment ,while the level of high-density lipoprotein cholesterol increased significantly in contrast with that of pre -treatment(all P<0.05).After the treatment, the levels of total cholesterol ,triglycerides ,low-density lipoprotein cholesterol of group C were significantly lower than those of group A and group B ,while the level of high-density lipoprotein cholesterol were significantly higher than that of group A and group B(all P<0.05).After the treatment,the compliance rates of cholesterol and low-density lipoprotein cholesterol of group C (86.67%,83.33%) were significantly higher than those of group A (56.67%,73.33%) and group B(53.33%,73.33%) ( P<0.05).The incidences of adverse reactions of groups A ,B and C were 6.67%, 6.67%and 10.00%,respectively .There were no serious adverse reactions .No significant difference was found in the incidence of adverse reactions among three groups (P>0.05).Conclusion Large doses of rosuvastatin calcium can control blood lipid level more effectively in elderly coronary heart disease patients with high safety .%目的：观察不同剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效和安全性。方法老年冠心病合并高脂血症患者90例，按随机数字表法分为A组、B组和C组各30例。3组患者均给予冠心病常规治疗方案进行治疗，A组患者加用5 mg瑞舒伐他汀钙口服，B组患者加用10 mg瑞舒伐他汀钙口服，C组患者加用20 mg瑞舒伐他汀钙口服，1次/d，晚餐后服用。治疗4个月后，对比3组患者的血脂水平达标率以及不良反应情况。结果3组患者治疗后的总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平均较治疗前显著下降，而高密度脂蛋白胆固醇水平则较治疗前显著升高（ P均＜0．05）；C组患者治疗后的总胆固醇、甘油三酯、低密度脂蛋白胆固醇水平均显著低于A组和B组，而高密度脂蛋白胆固醇水平则显著高于 A组和B组（ P均＜0．05）；C组患者治疗后胆固醇、低密度脂蛋白胆固醇的达标率（86．67％、83．33％）均显著高于A组和B组（56．67％、53．33％，73．33％、73．33％）（P＜0．05）；A组不良反应发生率为6．67％，B组为6．67％；C组为10．00％，均未出现严重的不良反应，3组不良反应发生率比较，差异无统计学意义（ P＞0．05）。结论大剂量瑞舒伐他汀钙能够更有效地控制老年冠心病患者的血脂水平，且安全性高。
展开▼
